2022
DOI: 10.2147/jbm.s342077
|View full text |Cite
|
Sign up to set email alerts
|

Acquired Haemophilia A: A Review of What We Know

Abstract: Autoantibodies against plasma coagulation factors could be developed by some individuals inducing severe and sometimes fatal bleedings. This clinical entity is called acquired haemophilia. It should be suspected in subjects with acute abnormal bleedings, without personal or familiar history of congenital bleeding disorders with an unexplained prolonged aPTT. It is rare disease, although its incidence may be underestimated due to the low knowledge about it by many specialists, the frequent use of anticoagulant … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
30
0
1

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 12 publications
(31 citation statements)
references
References 118 publications
0
30
0
1
Order By: Relevance
“…Patients with AHA present with isolated prolonged aPTT with abnormal bleeding symptoms, such as subcutaneous, muscle, gastrointestinal, genitourinary, or retroperitoneal bleeding [ 1 ]. Although more than 50% of cases are idiopathic, AHA possibly develops as a paraneoplastic syndrome [ 1 ]. Malignancies were reported to account for 6–18% of the underlying disease in AHA [ 3 , 7 9 ].…”
Section: Discussionmentioning
confidence: 99%
See 4 more Smart Citations
“…Patients with AHA present with isolated prolonged aPTT with abnormal bleeding symptoms, such as subcutaneous, muscle, gastrointestinal, genitourinary, or retroperitoneal bleeding [ 1 ]. Although more than 50% of cases are idiopathic, AHA possibly develops as a paraneoplastic syndrome [ 1 ]. Malignancies were reported to account for 6–18% of the underlying disease in AHA [ 3 , 7 9 ].…”
Section: Discussionmentioning
confidence: 99%
“…The treatment of AHA reportedly consists of four pillars: prevention of bleeding; treatment of the underlying disease; hemostatic treatment using an FVIII agent, desmopressin, and bypassing agents (rFVIIa or activated prothrombin complex); and immunosuppressive therapy (e.g., steroids, cyclophosphamide and rituximab) for eradication of the inhibitor [ 1 ]. To prevent bleeding, invasive procedures should be avoided if AHA develops in the perioperative period.…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations